Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Analys av helkroppsmagnetresonanstomografi och vätskebiopsi för tidig upptäckt av cancer hos patienter med en stark familjehistoria av cancer

2 november 2026 uppdaterad av: City of Hope Medical Center

Helkropps-MR och flytande biopsi för tidig upptäckt av cancer

This study evaluates patient acceptability of whole body magnetic resonance imaging (WBM) and liquid biopsies (LB) in detecting early stage cancer in patients with a strong family history of cancer. Collecting family history and testing for genes passed on from parent to child (germline testing) can be used to predict the likelihood of a patient developing cancer. Currently, detection of early cancers focuses on screening specific organ systems such as breast and colon cancer. Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside the body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to cancer. Liquid biopsy is test that analyzes blood samples to determine if cancer cells are present. This study may help researchers determine the feasibility of WBM and liquid biopsies to detect early stage cancer in patients that have a strong family history of cancer.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVE:

I. To assess the acceptability of the approach of LB and WBM.

SECONDARY OBJECTIVES:

I. Determine the prevalence of WBM findings requiring additional imaging or invasive testing.

II. Determine the effect of germline testing, LB, and WBM on psychological distress and health-related quality of life (HR-QOL) at 6 months after testing compared with baseline.

EXPLORATORY OBJECTIVE:

I. Determine correlation between high-risk LB findings and cancer detected on WBM.

OUTLINE: This is an observational study.

Patients undergo WBM without contrast, blood sample collection for liquid biopsy, and complete surveys on study. Germline testing may also be performed on blood sample collected as standard of care or using the Precision Medicine protocol (Institutional Review Board [IRB] 96144).

Studietyp

Interventionell

Inskrivning (Faktisk)

100

Fas

  • Tidig fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Duarte, California, Förenta staterna, 91010
        • City of Hope Medical Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age >= 50 years, or age within 10 years of first degree relative with cancer at age of diagnosis (as long as age is >= 18)
  • Have a strong family history of cancer ( >= 2 first-degree relatives with cancer, one first and second degree relative with cancer in one lineage (side of family), or at least three first or second degree relatives with cancer in one lineage (side of the family). Non-melanoma skin cancer excluded from family history eligibility
  • Have a family history of early-onset cancer (age >40) in at least one first-degree relative
  • Willing to have 50 mL of blood (approximately 3.5 tablespoons) drawn (40 ml if germline testing already performed)
  • Able to undergo MRI (no implants, metal, or claustrophobia that would preclude MRI)
  • Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer
  • Positron emission tomography/computed tomography (PET/CT) or other whole body imaging modality (including combination of CT chest and abdomen) within 3 years
  • No signs/symptoms of possible cancer (e.g. hemoptysis, breast mass, blood per rectum, unexplained weight loss)
  • Willing to undergo standard of care genetic counseling and germline testing, or has already undergone genetic counseling and germline testing
  • Documented informed consent of the participant

Exclusion Criteria:

  • Unable to provide informed consent
  • Contraindications to MRI (implants, metal, or claustrophobia that would preclude MRI)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Undersökning
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Whole Body MRI and Liquid Biopsy

Patients undergo WBM without contrast and blood sample collection for liquid biopsy

Undergo blood sample collection

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling

Complete surveys

Undergo germline testing

Andra namn:
  • Cancerriskbedömning med genetisk testning och rådgivning

Undergo liquid biopsy testing

Andra namn:
  • Plasmabiopsi

Undergo whole body MRI without contrast

Andra namn:
  • WB-MRI utan kontrast
  • Magnetisk resonanstomografi för hela kroppen utan kontrast
  • Helkropps-MR utan kontrast

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Acceptability of germline testing, liquid biopsy and whole body magnetic resonance imaging (WBM)
Tidsram: Up to 6 months after WBM

Acceptability, as measured by the survey question "How satisfied are you with the research study overall?" and is defined as a score of 4 ("moderately acceptable) or 5 ("highly acceptable").

Up to 6 months after WBM

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Prevalence of WBM findings requiring additional imaging or invasive testing
Tidsram: Up to 6 months after WBM

Prevalence of WBM findings requiring additional imaging or invasive testing, described as a per participant percentage.

Up to 6 months after WBM
Psychological distress (Germline testing)A
Tidsram: Up to 6 months after WBM

The effect of germline testing on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (Germline testing)B
Tidsram: Up to 6 months after WBM

The effect of germline testing on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (Liquid Biopsy)A
Tidsram: Up to 6 months after WBM

The effect of LB on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (Liquid Biopsy)B
Tidsram: Up to 6 months after WBM

The effect of LB on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (WBM)A
Tidsram: Up to 6 months after WBM

The effect of Whole Body MRI on Psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (WBM)B
Tidsram: Up to 6 months after WBM

The effect of Whole Body MRI on Psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.

Up to 6 months after WBM
Health Related Quality of Life (HRQOL/Germline)
Tidsram: Up to 6 months after WBM

The effect of germline testing on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Health Related Quality of Life (HRQOL/LB)
Tidsram: Up to 6 months after WBM

The effect of LB on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Health Related Quality of Life (HRQOL/WBM)
Tidsram: Up to 6 months after WBM

The effect of WBM on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Correlation between high-risk liquid biopsy findings and cancer detected on WBM
Tidsram: Up to 6 months after WBM

Liquid biopsy (LB) test sensitivity and specificity calculated by comparing the LB results with the WBM results, with WBM results considered the gold standard. Confusion matrix statistics, such as positive predictive value, negative predictive value, and test accuracy examined. Results reported with their corresponding 95% confidence intervals.

Up to 6 months after WBM

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Dan Raz, City of Hope Medical Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 maj 2022

Primärt slutförande (Beräknad)

20 september 2027

Avslutad studie (Beräknad)

20 september 2027

Studieregistreringsdatum

Först inskickad

29 mars 2023

Först inskickad som uppfyllde QC-kriterierna

19 maj 2023

Första postat (Faktisk)

22 maj 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera